PBN FASTEST GROWING COMPANIES 2020 $5M – $25M
5. EpiVax Inc.
CEO (or equivalent): Dr. Anne De Groot, CEO and chief scientific officer
2019 Revenue: $6.8 million
2017 Revenue: $4.7 million
Revenue growth: 44.7%
ONE COMPANY THAT BEGAN in a Brown University lab is finding that work in the microscopic world of immunology can help profits go viral.
Federal and State Nursing Home Staffing Mandates
Staffing has always been an ongoing challenge in the long-term care industry. However, since the…
Learn More
Providence-based EpiVax Inc.’s earnings grew to $6.8 million in 2019, a 44.7% boost of $2.1 million over three years.
The 20-year-old company uses cutting-edge tools founder Dr. Anne De Groot developed while at Brown to screen and analyze pharmaceuticals for unwanted responses from the immune system.
“That’s where we excel – is helping companies avoid a problem with their drugs,” said De Groot, EpiVax’s CEO and chief scientific officer.
This spring, EpiVax added a COVID-19 cure to its growing list of vaccines and immunotherapies under research and development for infectious diseases, autoimmunity and cancer.
EpiVax has also been licensing its novel immune-modulating Tregitope technology to pharmaceutical companies for their research and development.
“It’s a culture largely revolving around curiosity,” said Cliff Grimm, chief financial officer and business officer. “That’s what gets us to where we are.”
